Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 4 de 4
Heart ; 107(SUPPL 1):A91, 2021.
Article in English | EMBASE | ID: covidwho-1325144


Background Limitation of activity and restriction of movement have been widely, and effectively, enforced to reduce COVID- 19 transmission. Physical activity is however a critical measure in the prevention of cardiovascular disease. Pulmonary arterial hypertension (PAH) is a devastating, disease driven by small vessel vascular remodeling, leading to right heart failure. Exercise capacity relates to clinical outcomes and exercise training improves key indicators of cardiopulmonary function. Here, we describe the temporal effects of UK government restriction measures on daily activity, heart rate and quality-of-life (QoL) in patients with PAH. Methods From November 2019 to March 2020 patients were enrolled into the arrhythmia sub-study of The UK National Cohort Study of Idiopathic and Heritable PAH (REC:13/EE/ 0203) and implanted with insertable cardiac monitors. Daily heart rate, heart rate variability and activity were transmitted remotely. Standard questionnaires were administered remotely to assess QoL (EmPHasis-10), anxiety (GAD-7) and depression (PHQ-9). Results Median age of the 26 patients implanted with insertable cardiac monitors was 49 years, 23(88%) were female and 5(19%) had heritable PAH with mutations in BMPR2. At enrolment 10(38.5%) patients were low risk (<5% 1-year mortality), 10(38.5%) were intermediate risk (5-10%) and 6 (23%) were high risk (>10%). The mean duration from insertion to census date was 21.1weeks±5.7. No complications were reported. Completeness of remote monitoring data was 100%. Following lockdown, mean activity was reduced (3.16vrs 2.68hours, -0.48 hours, 95%CI -0.27-0.69, 16%, p<0.0001). During the period April 14th to 23rd QoL was reduced (26(18-38)vrs 32 (17-47), p<0.01) and anxiety (1(0- 9)vrs 10 (5-18), p<0.001) and depression scores increased (3 (1-16)vrs 11 (3-17), p<0.001) compared to pre-lockdown levels. The observed increase in depression scores persisted to the census date (3(1-16)vrs 11(8-17), p<0.01). No change in day or night heart rate, or heart rate variability, was observed and no patients developed COVID-19. Conclusion In this cohort of patients with idiopathic and heritable PAH, UK protective health measures were effective in preventing COVID-19 in patients thought to be vulnerable. However, these protective measures resulted in reduced daily activity and QoL and were associated increased anxiety and depression indicators. Patients may decondition through periods of reduced activity. This may have implications for riskassessment and endpoint adjudication in clinical studies, both of which use measures of exercise capacity.

Diagnostics ; 11(4):09, 2021.
Article in English | MEDLINE | ID: covidwho-1209859


Accurate phenotyping of patients with pulmonary hypertension (PH) is an integral part of informing disease classification, treatment, and prognosis. The impact of lung disease on PH outcomes and response to treatment remains a challenging area with limited progress. Imaging with computed tomography (CT) plays an important role in patients with suspected PH when assessing for parenchymal lung disease, however, current assessments are limited by their semi-qualitative nature. Quantitative chest-CT (QCT) allows numerical quantification of lung parenchymal disease beyond subjective visual assessment. This has facilitated advances in radiological assessment and clinical correlation of a range of lung diseases including emphysema, interstitial lung disease, and coronavirus disease 2019 (COVID-19). Artificial Intelligence approaches have the potential to facilitate rapid quantitative assessments. Benefits of cross-sectional imaging include ease and speed of scan acquisition, repeatability and the potential for novel insights beyond visual assessment alone. Potential clinical benefits include improved phenotyping and prediction of treatment response and survival. Artificial intelligence approaches also have the potential to aid more focused study of pulmonary arterial hypertension (PAH) therapies by identifying more homogeneous subgroups of patients with lung disease. This state-of-the-art review summarizes recent QCT developments and potential applications in patients with PH with a focus on lung disease.